MeiraGTx Holdings has signed a deal with Eli Lilly , potentially worth over $475 million, granting the pharma giant rights to ...

Lilly will also gain certain rights to MeiraGTx’s proprietary riboswitch technology for use in gene editing in the eye. Under ...

MeiraGTx Holdings plc stock surges after a major Eli Lilly partnership boosts funding and pipeline. Click for my updated look ...

MeiraGTx (MGTX) stock climbs as the company partners with Eli Lilly (LLY) to develop and sell gene therapies for eye diseases ...

Entered into broad strategic collaboration with Eli Lilly and Company (“Lilly”) in the area of ophthalmology, granting Lilly worldwide exclusive ...

LONDON and NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced a broad strategic ...

Lilly will also gain exclusive access to MeiraGTx’s gene therapy platform technologies, including novel intravitreal capsids ...

MeiraGTx shares rise after signing a $475 million deal with Eli Lilly for a gene therapy program restoring vision in children ...

MeiraGTx’s AAV-AIPL1 has already led to vision gains in blind children, as regulatory submissions for the gene therapy close ...

Eli Lilly is partnering with MeiraGTx to develop and commercialize ophthalmology gene therapies, and with SanegeneBio to ...

MeiraGTx Holdings shares rose sharply in premarket trading Monday after the clinical-stage genetic-medicines said it formed a ophthalmology collaboration potentially worth hundreds of millions of ...

The alliance extends a deal streak in genetic medicine for Lilly and hands the company rights to an experimental treatment ...